Literature DB >> 17638004

Effect of oral CDP-choline on visual function in young amblyopic patients.

Michela Fresina1, Anna Dickmann, Annabella Salerni, Fabio De Gregorio, Emilio C Campos.   

Abstract

PURPOSE: The purpose of the study was to evaluate the effect on visual function of orally administered CDP-choline in addition to patching for the treatment of amblyopia in children.
METHODS: This was an open label parallel group study comparing patching plus oral CDP-choline with patching alone. Sixty-one participants (aged between 5 and 10 years) suffering from anisometropic or strabismic amblyopia were divided at random into two groups: Group A, 800 or 1,200 mg (according to the body weight) of orally administered CDP-choline and 2-h patching a day; Group B, 2-h patching a day. Both groups were treated for 30 consecutive days. A follow-up visit was set 60 days after the treatment was discontinued. The main outcome measure was the change in visual acuity of amblyopic eyes as measured by Snellen's E charts. The secondary outcome measures were changes in the visual acuity of amblyopic eye as measured by isolated letters (Snellen's E) and changes in the contrast sensitivity of amblyopic eyes.
RESULTS: The addition of CDP-choline to patching therapy was not found to be more effective than patching alone after 30-day treatment. The present results showed that adding CDP-choline to patching stabilised the effects obtained during the treatment period. In fact, whereas the participants treated only with patching showed a decrease in visual acuity at 90 days, these receiving CDP-choline and patching combined appeared to maintain the results obtained (two-way ANOVA: P = 0.0042). Similar results were obtained when measuring visual acuity by isolated Snellen's E letters.
CONCLUSIONS: In amblyopic patients, CDP-choline combined with patching contributes to obtaining more stable effects than patching alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638004     DOI: 10.1007/s00417-007-0621-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  39 in total

1.  Prevalence of amblyopia among defaulters of preschool vision screening.

Authors:  D K Newman; M M East
Journal:  Ophthalmic Epidemiol       Date:  2000-03       Impact factor: 1.648

2.  [Landolt C and snellen e acuity: differences in strabismus amblyopia?].

Authors:  R Becker; M Gräf
Journal:  Klin Monbl Augenheilkd       Date:  2006-01       Impact factor: 0.700

3.  Activities of enzymes metabolizing phospholipids in rat cerebral ischemia.

Authors:  Y Hirashima; A Moto; S Endo; A Takaku
Journal:  Mol Chem Neuropathol       Date:  1989-04

Review 4.  Phospholipid metabolism.

Authors:  W C McMurray; W L Magee
Journal:  Annu Rev Biochem       Date:  1972       Impact factor: 23.643

5.  Visual acuities and scotomas after one week levodopa administration in human amblyopia.

Authors:  I Gottlob; J Charlier; R D Reinecke
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-08       Impact factor: 4.799

Review 6.  Visuo-cognitive dysfunctions in Parkinson's disease.

Authors:  A Antal; F Bandini; S Kéri; I Bodis-Wollner
Journal:  Clin Neurosci       Date:  1998

7.  Transport and metabolism of double-labelled CDPcholine in mammalian tissues.

Authors:  P Galletti; M De Rosa; M A Nappi; G Pontoni; L del Piano; A Salluzzo; V Zappia
Journal:  Biochem Pharmacol       Date:  1985-12-01       Impact factor: 5.858

8.  Degradation of phospholipid molecular species during experimental cerebral ischemia in rats.

Authors:  Y Goto; S Okamoto; Y Yonekawa; W Taki; H Kikuchi; H Handa; M Kito
Journal:  Stroke       Date:  1988-06       Impact factor: 7.914

9.  CDP-choline: 6-month study on toxicity in dogs.

Authors:  A Romero; T Grau; A Sacristán; J A Ortiz
Journal:  Arzneimittelforschung       Date:  1983

10.  Alteration of visual evoked potentials and electroretinograms in Parkinson's disease.

Authors:  I Gottlob; E Schneider; W Heider; W Skrandies
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1987-04
View more
  17 in total

Review 1.  [The latest on amblyopia treatment].

Authors:  O Ehrt
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

2.  The use of choline in association with the Bangerter filters for the treatment of amblyopia.

Authors:  Lelio Sabetti; Francesco Masedu; Chiara Tresca; Federica Bianchi; Marco Valenti
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

3.  Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma.

Authors:  Vincenzo Parisi; Marco Centofanti; Lucia Ziccardi; Lucia Tanga; Manuele Michelessi; Gloria Roberti; Gianluca Manni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-26       Impact factor: 3.117

Review 4.  The treatment of amblyopia: current practice and emerging trends.

Authors:  Eleni Papageorgiou; Ioannis Asproudis; Gail Maconachie; Evangelia E Tsironi; Irene Gottlob
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-31       Impact factor: 3.117

5.  Outcome of conventional treatment for adult amblyopia.

Authors:  Fumiko Kishimoto; Chiaki Fujii; Yoshie Shira; Kayoko Hasebe; Ichiro Hamasaki; Hiroshi Ohtsuki
Journal:  Jpn J Ophthalmol       Date:  2013-10-26       Impact factor: 2.447

Review 6.  An update on pharmacological treatment options for amblyopia.

Authors:  Aldo Vagge; Lorenzo Ferro Desideri; Carlo Enrico Traverso
Journal:  Int Ophthalmol       Date:  2020-08-07       Impact factor: 2.031

7.  Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial.

Authors:  Prachee Vasant Pawar; Sachin S Mumbare; Mrunal Suresh Patil; Seema Ramakrishnan
Journal:  Indian J Ophthalmol       Date:  2014-02       Impact factor: 1.848

Review 8.  Management of amblyopia in pediatric patients: Current insights.

Authors:  Sagnik Sen; Pallavi Singh; Rohit Saxena
Journal:  Eye (Lond)       Date:  2021-07-07       Impact factor: 3.775

Review 9.  Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives.

Authors:  Gloria Roberti; Lucia Tanga; Manuele Michelessi; Luciano Quaranta; Vincenzo Parisi; Gianluca Manni; Francesco Oddone
Journal:  Int J Mol Sci       Date:  2015-11-30       Impact factor: 5.923

Review 10.  Citicoline - a neuroprotector with proven effects on glaucomatous disease.

Authors:  Chitu Iulia; Tudosescu Ruxandra; Leasu-Branet Costin; Voinea Liliana-Mary
Journal:  Rom J Ophthalmol       Date:  2017 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.